Interferon therapies have been trialled in multiple cancer types, but efficacy has been hindered by dose-limiting toxicities.49 Trials using TLR agonists can induce IFN production, while causing fewer side effects compared with exogenous IFN treatment.49 Following treatment with poly(I:C), a number of human or mouse macrophages and DCs display the same transcriptional signalling and APP activation that distinguished good from poor prognostic HiFi tumours and was sufficient to reduce metastatic lesions in a HiFi-specific mouse model. The gene discussed is IFNA1; the disease is cancer.